Scholar Rock Holding Corp. is a pharmaceutical company based in the United States, specializing in developing innovative medicines to treat serious illnesses such as neuromuscular disorders, cancer, fibrosis, and anemia. They are known for their product candidate, Apitegroma, a selective, fully human monoclonal antibody that inhibits the activation of myostatin in skeletal muscle. Additionally, they offer SRK-181, an inhibitor of latent transforming growth factor beta-1 for treating cancers resistant to anti-PD-(L)1 therapies. With a medium-risk ESG score of 28.9, Scholar Rock's focus on environment, sustainability, and governance makes it a valuable player in the pharmaceutical industry.